...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432.
【24h】

Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432.

机译：接种胆固醇基支链淀粉（CHP）-NY-ESO-1和CHP-HER2与OK-432组合疫苗的患者对NY-ESO-1和HER2抗原的抗体反应。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Combination vaccines of the NY-ESO-1 protein complexed with cholesteryl pullulan (CHP), CHP-NY-ESO-1, and the truncated 146HER2 protein with CHP, CHP-HER2, were subcutaneously administered with the immuno-adjuvant OK-432 to eight esophageal cancer patients. Vaccination was well-tolerated. NY-ESO-1- and HER2-specific antibody responses were analyzed using the patients' sera and samples from previous single CHP-NY-ESO-1 or CHP-HER2 vaccine trial. The responses to NY-ESO-1 in the combination vaccine study were comparable to the single vaccine. For responses to HER2, there were fewer antibody responses in the combination vaccines. Although there were marked individual variations in the antibody responses to the NY-ESO-1 and HER2 antigens, the reaction patterns to these antigens were comparable within each patient. Antibodies to OK-432 were not augmented. Protein cancer vaccines targeting multiple antigens are feasible.
机译：将与胆固醇基支链淀粉（CHP），CHP-NY-ESO-1复合的NY-ESO-1蛋白和截短的146HER2蛋白与CHP，CHP-HER2复合的疫苗与免疫佐剂OK-432皮下给药八例食道癌患者。疫苗耐受性良好。使用患者的血清和先前单项CHP-NY-ESO-1或CHP-HER2疫苗试验的样品分析了NY-ESO-1-和HER2特异性抗体反应。联合疫苗研究中对NY-ESO-1的反应与单一疫苗相当。对于HER2的反应，联合疫苗中的抗体反应较少。尽管在针对NY-ESO-1和HER2抗原的抗体反应中存在明显的个体差异，但在每位患者中，针对这些抗原的反应模式是相当的。 OK-432的抗体没有增加。针对多种抗原的蛋白癌症疫苗是可行的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号